A Sign of Entering the Generic Market

Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Canagliflozin tablets (100mg and 300mg), a generic version of the type 2 diabetes medication. This approval, coinciding with the expiration of the patent for Janssen's blockbuster drug, Invokana, can be interpreted as a regulatory milestone in securing a foothold in the market for alternative medications. Aurobindo Pharma has a vertically integrated production line, from the synthesis of active pharmaceutical ingredients (APIs) to the manufacturing of finished products, which gives it a competitive advantage in terms of pricing compared to other generic pharmaceutical companies. As a result, millions of people with type 2 diabetes in the United States will have access to more affordable treatment options.

A Changing Landscape in the SGLT2 Inhibitor Market

Canagliflozin, an SGLT2 inhibitor ('Sodium-Glucose Cotransporter 2 Inhibitor'), is an innovative treatment option that lowers blood sugar by inhibiting the reabsorption of glucose in the kidneys and excreting it in the urine. The original drug, Invokana, was once very popular, with global sales reaching $792 million annually. However, with the emergence of strong competing drugs such as Jardiance (Empagliflozin) from Boehringer Ingelheim and Farxiga (Dapagliflozin) from AstraZeneca, its market share has been eroded. In this situation, Aurobindo Pharma's entry into the market with a low-cost generic is bound to increase the downward pressure on prices in the entire SGLT2 inhibitor market, which was previously dominated by high-priced branded drugs. This is expected to accelerate the shift in prescribing patterns from branded drugs to generic drugs.

Patent Disputes and Commercialization Timeline Variables

This FDA final approval is a regulatory milestone for market authorization, but the actual sale of the drug in pharmacies and the generation of revenue will depend on the patent dispute and exclusive rights agreements with the original developer, Janssen. Multinational pharmaceutical companies typically use strategies such as extending patent terms or filing patent lawsuits ('Paragraph IV Certification') to delay the entry of generics into the market for several years. Therefore, investors should watch to see whether Aurobindo Pharma can resolve the patent dispute early through an agreement and finalize a reasonable commercial launch schedule. If a patent agreement cannot be reached and the launch is delayed, the company may face the risk of slower initial market penetration and increased opportunity costs.

Reducing Healthcare Costs and Expanding Patient Access

The North American SGLT2 inhibitor market is a large and growing market, with a size of approximately $6.75 billion in 2023 and projected to reach $15 billion by 2033, with an annual growth rate of over 8%. This generic approval will be a powerful tool for negotiating the inclusion of the drug in the formularies of private and government health insurance plans ('Medicare/Medicaid') and significantly reducing prescription costs. In particular, the drug, which has broad indications including diabetes, diabetic nephropathy, and reduction of cardiovascular risk, will be converted to a generic, which will improve the soundness of public healthcare finances. As a result, patients will benefit from reduced out-of-pocket costs, and it will undoubtedly have a positive impact on the pharmaceutical market as a whole.